Risk Of Developing Liver Cancer After HCV Treatment

Monday, September 16, 2013

Doctor granted FDA emergency approval to use sofosbuvir/daclatasvir for hepatitis C transplant patient

Interesting -
Dr. Robert Fontana, professor of internal medicine and medical director of liver transplantation at U-M Health System, obtained emergency approval from the federal Food and Drug Administration to give Gholston a treatment that combined two oral antiviral medications, sofosbuvir and daclatasvir.

Drug therapy offers new hope to hepatitis C patients

September 16, 2013 at 1:00 am
Karen Bouffard 
The Detroit News
 
Troy — A new drug regimen for liver transplant patients — tried for the first time ever at the University of Michigan Hospital — could bring hope to millions of hepatitis C suffers and the man who received the initial treatment has made it his mission to educate the public about the disease.

Robert Gholston Jr., a 59-year-old General Motors Co. durability test driver from Troy, contracted the hepatitis C virus from a blood transfusion he received after he was hit by a car at age 9. By 2011, it had destroyed his liver, and he received a transplant at U-M Hospital. But within six months, the virus was back — and aggressively attacked his liver.

Dr. Robert Fontana, professor of internal medicine and medical director of liver transplantation at U-M Health System, obtained emergency approval from the federal Food and Drug Administration to give Gholston a treatment that combined two oral antiviral medications, sofosbuvir and daclatasvir.

Continue reading @ The Detroit News

3 comments: